We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+29.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.47B
AUM Growth
+$451M
(+5%)
Cap. Flow
+$1.13B
Cap. Flow
% of AUM
11.96%
Top 10 Holdings %
Top 10 Hldgs %
21.59%
Holding
903
New
107
Increased
255
Reduced
393
Closed
103
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$51.9M |
| 2 |
Merck
MRK
|
+$50.9M |
| 3 |
Danaher
DHR
|
+$45.3M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$37.8M |
| 5 |
JD.com
JD
|
+$37.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$103M |
| 2 |
Alibaba
BABA
|
+$98.6M |
| 3 |
Salesforce
CRM
|
+$62.5M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$59.4M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$48.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.61% |
| 2 | Technology | 20.94% |
| 3 | Consumer Discretionary | 8.9% |
| 4 | Financials | 8.59% |
| 5 | Communication Services | 7.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Wells Fargo
WFC
$263B
| $6.88M | 0.07% |
268,574
-110,420
| -29% | -$3.02M |
|
277
Pultegroup
PHM
$25.7B
| $6.81M | 0.07% |
200,027
+143,526
| +254% | +$4.31M |
|
278
Williams Companies
WMB
$85.8B
| $6.79M | 0.07% |
357,238
-46,627
| -12% | -$868K |
|
279
Personalis
PSNL
$1.27B
| $6.79M | 0.07% |
523,750
+278,443
| +114% | +$3.09M |
|
|
BNY
280
Bank of New York Mellon
BNY
$106B
| $6.74M | 0.07% |
174,486
-72,355
| -29% | -$2.65M |
|
281
TAL Education Group
TAL
$5.79B
| $6.71M | 0.07% |
98,183
-264,294
| -73% | -$15.1M |
|
|
QIWI
282
DELISTED
QIWI PLC
QIWI
| $6.65M | 0.07% |
383,800
-36,200
| -9% | -$491K |
|
|
FRC
283
DELISTED
First Republic Bank
FRC
| $6.56M | 0.07% |
61,893
+43,903
| +244% | +$4.51M |
|
284
Edwards Lifesciences
EW
$48.2B
| $6.49M | 0.07% |
93,837
-4,005
| -4% | -$285K |
|
285
Microchip Technology
MCHP
$41.1B
| $6.47M | 0.07% |
122,900
-118,690
| -49% | -$5.34M |
|
286
Guardant Health
GH
$19B
| $6.38M | 0.07% |
78,587
+20,829
| +36% | +$1.68M |
|
287
DexCom
DXCM
$28.9B
| $6.27M | 0.07% |
61,884
+34,852
| +129% | +$3.12M |
|
288
Southwest Airlines
LUV
$22.7B
| $6.24M | 0.07% |
182,439
-129,976
| -42% | -$4.13M |
|
|
DFS
289
DELISTED
Discover Financial Services
DFS
| $6.17M | 0.07% |
123,197
-84,284
| -41% | -$3.71M |
|
290
Equitable Holdings
EQH
$13.5B
| $6.14M | 0.06% |
+318,494
| New | +$5.69M |
|
291
Cummins
CMI
$88.5B
| $6.12M | 0.06% |
35,310
+6,297
| +22% | +$1.01M |
|
|
PTLA
292
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $6.09M | 0.06% |
256,198
+157,898
| +161% | +$2.2M |
|
293
VF Corp
VFC
$7.16B
| $6.02M | 0.06% |
98,807
+20,675
| +26% | +$1.2M |
|
|
ESPR
294
DELISTED
Esperion Therapeutics
ESPR
| $5.99M | 0.06% |
116,804
-98,292
| -46% | -$4.11M |
|
295
D.R. Horton
DHI
$42.3B
| $5.95M | 0.06% |
107,225
-52,519
| -33% | -$2.55M |
|
296
ServiceNow
NOW
$114B
| $5.93M | 0.06% |
73,250
-10,565
| -13% | -$746K |
|
297
KLA
KLAC
$249B
| $5.89M | 0.06% |
302,740
+147,160
| +95% | +$2.52M |
|
298
Cheniere Energy
LNG
$52.8B
| $5.88M | 0.06% |
121,664
-13,723
| -10% | -$599K |
|
299
McKesson
MCK
$104B
| $5.86M | 0.06% |
38,202
-10,855
| -22% | -$1.57M |
|
300
Progressive
PGR
$128B
| $5.65M | 0.06% |
70,474
-20,266
| -22% | -$1.58M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2020 Portfolio in Review
As of Q2 2020, Candriam SCA held 903 positions worth $9.47B, up 5% from $9.02B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $1.13B of net new capital in Q2 2020, opening 107 new positions and adding to 255 existing holdings. Its largest new stake was JD.com: 744,410 shares worth $44.8M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 31% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $103M trimmed.
- Candriam SCA's largest Q2 2020 buy was JD.com: 744,410 shares worth $44.8M.
- Candriam SCA added most to Blueprint Medicines in Q2 2020, an estimated $51.9M increase.
- Candriam SCA's biggest Q2 2020 reduction was Regeneron Pharmaceuticals, cutting an estimated $103M.
- Candriam SCA fully exited Salesforce in Q2 2020, selling an estimated $62.5M.
- Candriam SCA's ten largest holdings make up 22% of its $9.47B portfolio in Q2 2020.
- Candriam SCA opened 107 new positions and closed 103 in Q2 2020.
- Candriam SCA's portfolio value rose 5% quarter-over-quarter to $9.47B.
Based on Candriam SCA's 13F filing for Q2 2020, filed 23 Jul 2020.